Merck 2021 Research Grants: Stimulating Innovative Research In Challenging Areas Of Future Importance
Announcement posted by Merck Pty Ltd. Merck Life Science 24 May 2021
BAYSWATER, Australia, 24 May 2021—Merck, a leading science and technology company, announced its 2021 Research Grants program is now open, stimulating innovative research in challenging areas of future importance.
As part of our commitment to advance science and technology, Merck KGaA, Darmstadt, Germany, launched the research grants program. The Research Grants aim to create new sustainable partnerships with leading global science and technology players to work on breakthrough science and to generate valuable seeds for future business.
In 2021, Merck KGaA, Darmstadt, Germany, intends to offer grants in several areas of up to 450,000€ per year for up to 3 years with the option of extension or expansion. We intend to provide research grants in the following research areas:
Drug Discovery
Next game-changing technology / molecule to cure cancer or autoimmune disease. Three grants of €350,000/year for 3 years.
Real time testing and sensors
State-of-the-art of in-line or at-line monitoring during the production of biopharmaceuticals. Grant of $100,000 - $500,000/year for 2 years.
Nanoparticle for nucleic acid delivery
Novel, inventive delivery vehicles, formulations, routes of delivery, targeting strategies, considering manufacturing and stability. Grant of $100,000 - $300,000/year for 2 years.
Digital Innovation
Digital pathology image analysis, Single-Cell RNASeq analysis pipelines and AI-driven solutions using research and clinical data. Three grants of €40,000 - €100,000 for 1 year.
Bioelectronics
Novel solutions and biosensor technologies for remote patient monitoring in chronic inflammatory disorders Grant of €150,000/year for 3 years.
Sustainability
New sustainable products, technologies, sources, processes, business models.
Media recycling for cultured meat
Conceptual designs, deployment strategies and equipment for low cost and efficient systems.
Organoids
3D cell culture solutions with a focus on pre-clinical drug discovery and personalized medicine.
We are looking for innovative research proposals from scientists worldwide. Top submitters will be invited to a deep dive workshop to further advance the proposals together with our scientists. The deep dive workshop will include a decision on grant recipients. Merck will then enter into bilateral collaboration agreements with the winning recipients to enable pay-out of the research grant and project to start in 2022. A detailed description of the challenges, FAQs on the application process and timing of the deep-dive workshops are available at: https://www.merckgroup.com/en/research/open-innovation/2021-research-grants.html
The submission deadline is 31 August 2021.
ENDS
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.